Displaying 1–10 of 17 news results
Feb 13, 2023
The Foundation Makes an Impact on Retinal Research
The Foundation Fighting Blindness’ long-term impact on moving the inherited retinal disease field forward towards treatments and cures.
Apr 22, 2022
Foundation Summit Highlights Robust Growth in Commercial Development for Retinal Disease Therapies
The Foundation’s Investing in Cures Summit (ICS), held on April 2, 2022, in Half Moon Bay, California, convened 175 researchers, industry executives, and constituents to present and discuss the expanding and accelerating commercial development of emerging therapies for retinal degenerative diseases.
Jul 20, 2021
Statement from Ben Yerxa, PhD, about Paralympian Becca Meyers
The Foundation believes that all people with disabilities should receive the accommodations necessary for their inclusion in all facets of society, especially when an individual may be unfamiliar with the area.
Oct 6, 2020
Sign Up for Foundation Fighting Blindness Emails
May 7, 2020
Foundation and Vision Partners Seek Biomedical Research Support from Congress during COVID-19 Crisis
Delays in Research Impacting Therapy Development
Mar 31, 2020
The Foundation Fighting Blindness is closely monitoring the COVID-19 situation and its impact on the IRD community.
Feb 3, 2020
7th Annual Retinal Cell and Gene Therapy Innovation Summit
Please note that the seventh annual Retinal Cell and Gene Therapy Innovation Summit previously scheduled for Friday, May 1st, 2020 in Baltimore, Maryland has been cancelled.
Jan 29, 2020
VISIONS 2020 Conference registration now open
The Foundation Fighting Blindness VISIONS 2020 conference will be held on June 18-20th at the Hyatt Regency Minneapolis.
Aug 16, 2019
Foundation Fighting Blindness Investing Nearly $6.5 Million in New Grants
The newly funded research efforts include several therapies that have strong potential to treat a wide range of inherited retinal diseases.
Jun 3, 2019
Tackling the Next Gene Therapy Challenge: Autosomal Dominant Diseases
A discussion of strategies concerning the development of autosomal dominant disease therapies at the Translational Research Acceleration Program (TRAP) in November 2013.